WORLD MEDICAL INNOVATION FORUMSM | APRIL 25–27, 2016 World Medical Innovation Forum

PARTNERS HEALTHCARE

Headquartered in Boston, The World Medical Innovation Forum is a global , Partners HealthCare gathering of more than 1,200 senior health care is one of the nation's most highly leaders hosted by Partners HealthCare in the regarded hospital systems. Its founding institutions, Brigham and heart of Boston. It was established to respond to Women’s Hospital and Massachusetts the intensifying transformation of health care and General Hospital, are staffed by its impact on innovation. The Forum is rooted in faculty the belief that no matter the magnitude of that and have a legacy of innovation change, the center of health care needs to be a that includes 18 Nobel Laureates and therapies that have redefined shared, fundamental commitment to collaborative the contemporary standard of care. innovation – industry and academia working It's the largest academic research together to improve patient lives. enterprise in the nation at more than $1.5 billion of annual research. The 2016 World Medical Innovation Forum will Its staff is responsible for hundreds feature the newest technologies to diagnose, treat of products and best practices and manage cancer. that benefit millions of patients worldwide.

CANCER | April 25–27, 2016 CARDIOVASCULAR | May 1–3, 2017 Keynoters

Joseph Jimenez Giovanni Caforio, MD CEO, Novartis CEO, Bristol-Myers Squibb Robert Bradway Richard Gonzalez CEO, Amgen CEO, AbbVie Robert Mulroy Michael Pellini, MD CEO, Merrimack Pharmaceuticals CEO, Foundation Medicine Briggs Morrison, MD David Schenkein, MD CEO, Syndax Pharmaceuticals CEO, Agios Pharmaceuticals David Lee Bruno Strigini CEO, Lumicell President, Novartis Marc de Garidel William Hait, MD, PhD CEO, Ipsen Global Head, Janssen R&D, J&J Paul Hudson Gary Reedy President, AstraZeneca US, CEO, American Cancer Society Executive Vice President, Thomas Lynch, MD AstraZeneca North America CEO, Mass General David Torchiana, MD Physician’s Organization CEO, Partners HealthCare Monica Bertagnolli, MD Daniel Haber MD, PhD Chief, Division of Surgical Oncology, Director, Massachusetts General Hospital Brigham and Women’s Hospital, Cancer Center, Kurt J. Isselbacher/Peter D. Professor of Surgery, Schwartz Professor of Oncology, Harvard Medical School Harvard Medical School Judy Salerno, MD Glenn Dranoff , MD CEO, Susan G. Komen for the Cure Global Head of Exploratory Immuno- William Sellers, MD Oncology, Novartis Institutes for Vice President and Global Head of Biomedical Research Oncology, Novartis Institutes for Christopher Viehbacher BioMedical Research Managing Partner, Gurnet Point Capital Nancy Snyderman, MD Henri Termeer Medical Advisor, Jean-François Formela, MD GE Healthymagination Partner, Atlas Venture Amir Nashat, PhD Bob Tepper, MD Managing Partner, Polaris Partners Partner, Third Rock Ventures Jim Robinson Kathy Giusti President, Astellas Pharma US Founder and Executive Chairman, MMRF Francis Cuss, MD Executive Vice President and Chief Scientifi c Offi cer, R&D, Bristol-Myers Squibb

Every Speaker an Expert. Every Panel Unique. Every Seat Invaluable. Featured speakers include more than 100 CEOs, top cancer innovators, leading investors, and national journalists. Sponsors Panels

PRESENTING MON. APRIL 25, 2016 8:00 AM - 8:00 PM TUES. APRIL 26, 2016 8:15 AM - 6:45 PM WED. APRIL 27, 2016 8:10 AM - 1:20 PM STAKEHOLDER A War or Moonshot: Where Do We Stand? Arms Race in Radiation Breakthrough Devices to Treat Cancer Building and Managing a Disruptive Cancer Pipeline Cancer Diagnostics: New Uses, New Reimbursements? Combination Cancer Therapies: Drug Resistance and Therapeutic Index Curative Therapies: Game Changing Science and its New Economics STRATEGIC Discovery Cafe: Top Faculty Share Their Work Disruptive Dozen Early Detection and Prevention of Cancer and Novel Cancer Targets First Look: The Next Wave of Cancer Breakthroughs Funding the Next Cancer Companies Global Economics of Cancer: Markets in Transition Immunotherapy I: Checkpoint Activation and Cancer Vaccines Immunotherapy II: Cell Based Therapies COLLABORATORS New Philanthropy: Patients Driving Innovation Study Designs to Meet the Challenges of Personalized Cancer Medicines Successful Portfolio Strategy Surviving Cancer: New Realities, New Needs Breakthrough Technologies

FIRST LOOK The Next Wave of Cancer Breakthroughs Monday Morning | 8AM – 12PM DISCOVERY CAFÉ LUNCH Enjoy Lunch with Top Cancer Leadership Please join us as some of our most creative investigators from across Partners HealthCare describe their most promising commercially related research. Rapid-fire presentations by two dozen early-career Monday Lunch | 12PM – 1:30PM Harvard Medical School faculty will highlight compelling Top faculty from Brigham and Women's Hospital, new discoveries and insights that will be the cancer care Massachusetts General Hospital and Dana-Farber Cancer products of the future. If identifying new high impact cancer Institute will host intimate lunch discussions on developments technology is your passion—as an investor, company leader, in their field and their own research. Forum attendees are donor, entrepreneur or investigator—this session is for you. invited to engage with these internationally renowned leaders These young stars from Brigham and Women's Hospital, on topics ranging from the integration of specific oncology Massachusetts General Hospital and Dana-Farber Cancer therapies to the newest diagnostic methods. This will be an Institute will each describe their work in highly organized exciting and energized session with abundant opportunities 10-minute sessions. for direct exchanges with these world leaders. Open registration for tables by topic/speaker (8 guests per table) is Speakers available as part of World Forum registration. All speakers are affiliated with Harvard Medical School Cyril Benes, PhD, MGH Speakers Priscilla Brastianos, MD, MGH All speakers are affiliated with Harvard Medical School Mark Cobbold, MD, PhD, MGH Kenneth Anderson, MD, BWH Ryan Corcoran, MD, PhD, MGH Monica Bertagnolli, MD, BWH Jeannie Lee, MD, PhD, MGH Shawn Demehri, MD, PhD, MGH Joan Brugge, PhD, HMS Maximo Loda, MD, BWH Daniela Dinulescu, PhD, BWH George Demetri, MD, Jay Loeffler, MD, MGH Ritu Gill, MD, BWH Dana-Farber Robert Martuza, MD, MGH Wilhelm Haas, PhD, MGH Don Dizon, MD, MGH Marcela Maus, MD, PhD, Lida Hariri, MD, PhD, MGH David Fisher, MD, PhD, MGH MGH Aditi Hazra, PhD, BWH Keith Flaherty, MD, MGH Ann Partridge, MD, Jayender Jagadeesan, PhD, BWH Levi Garraway, MD, PhD, Dana-Farber Hakho Lee, PhD, MGH Dana-Farber Scott Rodig, MD, PhD, BWH Alexander Lin, PhD, BWH Jeffrey Golden MD, BWH Deborah Schrag, MD, BWH, Dana-Farber Sandra McAllister, PhD, BWH Daniel Haber, MD, PhD, MGH Arlene Sharpe, MD, PhD, Mikael Pittet, PhD, MGH Elizabeth Henske, MD, BWH, Dana-Farber BWH, Dana-Farber Miguel Rivera, MD, MGH Theodore Hong, MD, MGH Julie Silver, MD, Spaulding Sandro Santagata, MD, PhD, BWH John Iafrate, MD, MGH Kimberly Stegmaier, MD, Shiladitya Sengupta, PhD, BWH Dana-Farber Katherine Janeway, MD, Paul Shyn, MD, BWH Dana-Farber Guillermo Tearney, MD, MGH Matthew Steinhauser, MD, BWH Keith Joung, MD, PhD, MGH Ralph Weissleder, MD, PhD, Shannon Stott, PhD, MGH MGH Cigall Kadoch, PhD, Mario Suva, MD, PhD, MGH Dana-Farber Jonathan Whetstine, PhD, David Ting, MD, MGH MGH Featured Speakers

Kenneth Anderson, MD Sheila Dharmarajan Jeffrey Golden, MD Director, Jerome Lipper Multiple Myeloma Head of Business Development, Chair of Pathology, Brigham and Women's Center, Kraft Family Professor of Medicine, Zelnick Media Capital Hospital, Ramzi S. Cotran Professor of Harvard Medical School Keith Dionne, PhD Pathology, Harvard Medical School Usman Azam, MD CEO, Constellation Pharmaceuticals Richard Gonzalez Global Head, Cell & Gene Therapies Don Dizon, MD CEO, AbbVie Unit, Novartis Clinical Co-Director, Gynecologic Marc Grodman, MD Monica Bertagnolli, MD Oncology, Massachusetts General CEO, BioReference Laboratories Chief, Division of Surgical Oncology, Hospital, Associate Professor of Daphne Haas-Kogan, MD Brigham and Women's Hospital, Medicine, Harvard Medical School Chair, Department of Radiation Oncology, Professor of Surgery, Glenn Dranoff, MD Dana-Farber Cancer Institute, Harvard Medical School Global Head of Exploratory Immuno- Professor of Radiation Oncology, James Bradner, MD Oncology, Novartis Institutes for Harvard Medical School President, Novartis Institutes Biomedical Research Daniel Haber, MD, PhD for BioMedical Research Jens Eckstein, PhD Director, Massachusetts General Robert Bradway President, SR One Hospital Cancer Center, Kurt J. CEO, Amgen Helmy Eltoukhy, PhD Isselbacher/Peter D. Schwartz Professor of Troy Brennan, MD CEO, Guardant Health Oncology, Harvard Medical School EVP and CMO, CVS Health Jeffrey Engelman, MD, PhD Nir Hacohen, PhD Joan Brugge, PhD Director, Thoracic Oncology and Director, Immunologist, Center for Immunology Professor, Director, Ludwig Center, Molecular Therapeutics, Medical and Inflammatory Diseases, Massachusetts Harvard Medical School Oncology, Massachusetts General Hospital, General Hospital Associate Professor, Medicine, Harvard Medical School Giovanni Caforio, MD Laurel Schwartz Associate Professor of CEO, Bristol-Myers Squibb Medicine, Harvard Medical School William Hait, MD, PhD Global Head, Janssen R&D, J&J Bruce Chabner, MD Maurice Ferre, MD Cancer Center Clinical Director CEO, Insightec Sean Harper, MD Emeritus, Massachusetts General Tim Ferris, MD Executive Vice President, Hospital, Professor, Department of Senior Vice President of Population Health Research and Development, Amgen Medicine, Harvard Medical School Management, Partners HealthCare Stephen Hodi, MD Andy Chan, MD David Fisher, MD, PhD Director, Melanoma Center, Director, Program Director, Gastroenterology Chief, Dermatology, Center for Immuno-Oncology, Training Program, Massachusetts General Massachusetts General Hospital, Edward Dana-Farber Cancer Institute, Hospital, Associate Professor of Medicine, Wigglesworth Professor of Dermatology, Associate Professor of Medicine, Harvard Medical School Harvard Medical School Harvard Medical School Antonio Chiocca, MD, PhD Keith Flaherty, MD Theodore Hong, MD Chairman, Neurosurgery, Brigham and Director, Clinical Research, Cancer Director, Gastrointestinal Radiation Women's Hospital Professor of Surgery, Center, Massachusetts General Oncology, Massachusetts General Harvard Medical School Hospital, Associate Professor of Hospital, Associate Professor of Radiation Oncology, Harvard Medical School Robert Copeland, PhD Medicine, Harvard Medical School President of Research and Pat Fortune, PhD Paul Hudson Chief Scientific Officer, Epizyme Senior Market Sector Leader, President, AstraZeneca US, Partners Innovation Executive Vice President, Newt Crenshaw AstraZeneca North America Vice President of North America Jean-François Formela, MD Oncology, Eli Lilly Partner, Atlas Ventures John Iafrate, MD, PhD Associate in Pathology, Medical Director, Francis Cuss, MD Jamie Freedman, MD, PhD Center for Integrated Diagnostics, Executive Vice President Senior Vice President, Global Clinical Massachusetts General Hospital, and Chief Scientific Officer, R&D, Development MedImmune Associate Professor of Pathology, Bristol-Myers Squibb Mark Frohlich, MD Harvard Medical School Thomas Daniel, MD EVP, Development and Portfolio Strategy, Joseph Jachinowski Chairman, Celgene Research Juno Therapeutics CEO, Mevion Medical Systems Marc de Garidel Levi Garraway, MD, PhD Katherine Janeway, MD CEO, Ipsen Director, Center for Cancer Precision Associate Physician, Dana-Farber Louis DeGennaro, PhD Medicine, Assistant Professor of Medicine, Cancer Institute, Assistant Professor, CEO, The Leukemia Medical Oncology Service, Dana-Farber Harvard Medical School & Lymphoma Society Cancer Institute, Associate Professor of Medicine, Harvard Medical School Joseph Jimenez George Demetri, MD CEO, Novartis Director, Center for Sarcoma and Bone Kathy Giusti Oncology, Senior Vice President for Founder and Executive Chairman, MMRF Experimental Therapeutics, Institute Physician, Dana-Farber Cancer Institute Keith Joung, MD, PhD Briggs Morrison, MD Nancy Simonian, MD Associate Chief of Pathology for Research, CEO, Syndax Pharmaceuticals CEO, Syros Pharmaceuticals Associate Pathologist, Massachusetts Robert Mulroy Peter Slavin, MD General Hospital, Associate Professor of CEO, Merrimack Pharmaceuticals President, Massachusetts General Pathology, Harvard Medical School Betsy Nabel, MD Hospital, Professor of Healthcare Policy, Cigall Kadoch, PhD President, Brigham and Women's Harvard Medical School Principal Investigator, Pediatric Oncology, Hospital, Professor of Medicine, Nancy Snyderman, MD Dana-Farber Cancer Institute, Harvard Medical School Medical Advisor, Assistant Professor, Pediatrics, GE Healthymagination Harvard Medical School Amir Nashat, PhD Managing Partner, Polaris Partners Risa Stack, PhD Anne Klibanski, MD Ann Partridge, MD General Manager, New Business Creation, Chief Academic Officer, GE Ventures Partners HealthCare, Laurie Carrol Director, Adult Survivorship Program, Guthart Professor of Medicine, Program for Young Women with Breast Billy Starr Harvard Medical School Cancer, Dana-Farber Cancer Institute, Founder & Executive Director, Maria Koehler, MD, PhD Associate Professor of Medicine, Pan-Mass Challenge Vice President, Oncology Strategy, Harvard Medical School Kimberly Stegmaier, MD Innovation and Collaborators, Michael Pellini, MD Associate Professor, Dana-Farber Cancer Oncology CEO, Foundation Medicine Institute, Harvard Medical School Krishna Kumar Amy Pollack, MD Bruno Strigini CEO, Emerging Business, Phillips Vice President, Medical Affairs, CMO, President, Novartis Oncology Peter Lebowitz, MD, PhD Surgical Businesses and Developed Guillermo Tearney, MD, PhD Global Therapeutic Area Head, Markets, Covidien Pathologist, Massachusetts General Oncology, Janssen R&D Gary Reedy Hospital, Professor of Pathology, David Lee CEO, American Cancer Society Harvard Medical School CEO, Lumicell David Reese, MD Robert Tepper, MD Jeannie Lee, MD, PhD Senior Vice President, Partner, Third Rock Ventures, Adjunct Professor of Genetics, Translational Sciences, Amgen Professor, Harvard Medical School Massachusetts General Hospital Alessandro Riva, MD Henri Termeer Jonathan Leff Global Head, Oncology Development and Claire Thom Partner, Deerfield Investments Medical Affairs, Novartis Oncology Senior Vice President, Global Oncology Gillian Leng, MD James Robinson Development, Astellas Deputy Chief Executive and Director of President, Astellas Pharma US Meg Tirrell Health and Social Care, NICE Scott Rodig, MD, PhD Biotech and Pharma Reporter, CNBC Nick Leschly Associate Professor, David Torchiana, MD CEO, Bluebird Bio Brigham and Women's Hospital CEO, Partners HealthCare Neal Lindeman, MD Phil Rowlands, PhD Mike Vasconcelles, MD Associate Pathologist, Pathology, Interim Head, Oncology, CMO, Unum Therapeutics Therapeutic Area Unit, Takeda Brigham and Women's Hospital, Christopher Viehbacher Associate Professor, Pathology, Judy Salerno, MD Managing Partner, Harvard Medical School CEO, Susan G. Komen for the Cure Gurnet Point Capital Massimo Loda, MD David Schenkein, MD Ralph Weissleder, MD, PhD Senior Pathologist, Principal Investigator, CEO, Agios Pharmaceuticals Director, Center for Systems Biology, Brigham and Women's Hospital, Deborah Schrag, MD Massachusetts General Hospital, Dana-Farber Cancer Institute, Professor, Chief, Division of Population Sciences, Professor, Radiology and Systems Department of Pathology, Medical Oncology, Dana-Farber Cancer Biology, Harvard Medical School Harvard Medical School Institute Professor, Medicine, Johnathan Whetstine, PhD Jay Loeffler, MD Harvard Medical School Tepper Family Research Scholar, Chair, Radiation Oncology, Massachusetts William Sellers, MD Massachusetts General Hospital, General Hospital, Herman and Joan Suit Vice President and Global Head of Associate Professor of Medicine, Professor of Radiation Oncology, Oncology, Novartis Institutes for Harvard Medical School Harvard Medical School BioMedical Research Chuck Wilson, PhD David Louis, MD Arlene Sharpe, MD, PhD CEO, Unum Therapeutics Pathologist-in-Chief, Massachusetts Leader, Cancer Immunology Brigham and Dow Wilson General Hospital, Benjamin Castleman Women's Hospital, Dana-Farber Cancer CEO, Varian Medical Systems Professor of Pathology, Institute, George Fabyan Professor of Harvard Medical School Comparative Pathology, Note: Speakers subject to change. Thomas Lynch, MD Harvard Medical School CEO, Mass General Julie Silver, MD Physician's Organization Associate Professor, Associate Chair, Marcela Maus, MD, PhD Strategic Initiatives, Department of Director of Cellular Immunotherapy, Physical Medicine and Rehabilitation, Massachusetts General Hospital, Assistant Harvard Medical School Professor, Harvard Medical School Join Us for the 2016 World Medical Innovation Forum

Experience the state-of-the-art in cancer technology, care, and research

Understand the prospects for innovation in a transformed health care industry

See firsthand the breakthrough cancer technologies from across the industry

Forge relationships and exchange information with world-recognized clinicians, investors, entrepreneurs, scientists, CEOs, executives, government leaders, philanthropists, and journalists

BROUGHT TO YOU BY:

215 First Street, Suite 500 | Cambridge, MA 02142 worldmedicalinnovation.org